Braun Stacey Associates Inc. Sells 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Braun Stacey Associates Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,492 shares of the biopharmaceutical company’s stock after selling 654 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $15,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Private Wealth Management Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the period. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $39,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent analyst reports. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Down 0.1 %

Shares of Regeneron Pharmaceuticals stock opened at $673.60 on Tuesday. The business has a 50-day moving average of $706.92 and a two-hundred day moving average of $894.87. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company has a market capitalization of $74.02 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.